Um estudo para avaliar o efeito de longo prazo do TEV-48574 na colite ulcerosa moderada a grave ou na doença de Crohn
Um estudo de extensão de longo prazo de fase 2b de 24 semanas, randomizado, duplo-cego para determinar a farmacocinética, eficácia, segurança e tolerabilidade de longo prazo do TEV-48574 em pacientes adultos com colite ulcerosa moderada a grave ou doença de Crohn que completaram a Fase Principal do Estudo de Variação de Dose (RELIEVE UCCD LTE)
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).
Secondary objectives of the study are to:
- evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
- evaluate the safety and tolerability of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
- evaluate the immunogenicity of 2 different maintenance dose regimens of TEV-48574 sc administered Q4W in adult participants with IBD
The total duration for a participant in the double-blind period only is 66 weeks; and for a participant in the open-label extension (OLE) period, up to an additional 268 weeks.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Kiel, Alemanha, 24105
- University Hospital Schleswig-Holstein
-
Tübingen, Alemanha, 72076
- University Hospital Tuebingen
-
Ulm, Alemanha, 89081
- University Hospital Ulm
-
Wipperfürth, Alemanha, 51688
- Group Practice Jakobeit
-
-
-
-
-
Gorna Oryahovitsa, Bulgária, 5100
- Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD
-
Sofia, Bulgária, 1618
- 20th Diagnostic Consultancy Center, Sofia
-
Sofia, Bulgária, 1784
- University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic, Sofia
-
-
-
-
-
Bardejov, Eslováquia, 085 01
- ALIAN, s.r.o.
-
Bratislava, Eslováquia, 811 09
- Cliniq, s.r.o.
-
Košice, Eslováquia, 040 13
- Endomed, s.r.o.
-
Prešov, Eslováquia, 080 01
- GASTRO I, s.r.o.
-
Prešov, Eslováquia, 080 01
- Gastro LM s.r.o.
-
-
-
-
-
Huelva, Espanha, 21005
- Juan Ramon Jimenez Hospital
-
Santiago de Compostela, Espanha, 15702
- Gaias Santiago Clinic
-
Valencia, Espanha, 46026
- University and Polytechnic Hospital La Fe
-
-
-
-
California
-
San Diego, California, Estados Unidos, 92103
- Clinical Applications Laboratories Inc
-
-
Florida
-
Kissimmee, Florida, Estados Unidos, 34741
- I.H.S. Health
-
Orlando, Florida, Estados Unidos, 32803
- Endoscopic Research, Inc.
-
Pinellas Park, Florida, Estados Unidos, 33781
- Gastro Florida
-
-
Illinois
-
Gurnee, Illinois, Estados Unidos, 60031
- Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee
-
-
Indiana
-
New Albany, Indiana, Estados Unidos, 47150
- Gastroenterology Health Partners, PLLC
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40218
- Gastroenterology Health Partners, PLLC - Central Louisville
-
-
Missouri
-
Liberty, Missouri, Estados Unidos, 64068
- BVL Clinical Research
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89128.
- Vector Clinical Trials
-
-
Ohio
-
Beavercreek, Ohio, Estados Unidos, 45440
- Dayton Gastroenterology, LLC - Beavercreek
-
-
Texas
-
Harlingen, Texas, Estados Unidos, 78550
- Texas Digestive Specialists
-
Katy, Texas, Estados Unidos, 77494
- Gastro Health & Nutrition - Katy
-
San Antonio, Texas, Estados Unidos, 78229
- Gastroenterology Research of San Antonio LLC
-
Southlake, Texas, Estados Unidos, 76092
- Texas Digestive Disease Consultants, PLLC. dba GI Alliance - Southlake
-
Tyler, Texas, Estados Unidos, 75701
- Tyler Research Institute, LLC
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84124
- Care Access
-
-
-
-
-
Tbilisi, Geórgia, 0119
- Israeli - Georgian Medical Research Clinic Healthycore LLC
-
Tbilisi, Geórgia, 0180
- Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
-
-
-
-
-
Budapest, Hungria, H-1033
- Clinexpert Ltd. Budapest
-
Budapest, Hungria, 1085
- Semmelweis University, Department of Internal Medicine and Hematology
-
Vác, Hungria, H-2600
- Javorszky Odon Hospital Vac
-
-
-
-
-
Afula, Israel, 1834111
- HaEmek Medical Center
-
Beersheba, Israel, 8410101
- Soroka University Medical Center
-
-
-
-
-
Milan, Itália, 20132
- Hospital San Raffaele, IRCCS
-
Milan, Itália, 20157
- ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo University
-
Rozzano, Itália, 20089
- Clinical Institute Humanitas, IRCCS
-
-
-
-
-
Kashiwa, Japão, 277-0871
- Kokikai Tsujinaka Hospital Kashiwanoha, Department of Gastroenterology
-
Minato, Japão, 108-8642
- Kitasato University Kitasato Institute Hospital
-
Sakura, Japão, 285-8741
- Toho University Sakura Medical Center, Department of Gastroenterology
-
Shinjuku, Japão, 169-0073
- Tokyo Yamate Medical Center, Department of Gastroenterology
-
Toyama, Japão, 930-8550
- Toyama Prefectural Central Hospital, Department of Internal Medicine, Gastroenterology
-
-
-
-
-
Lorenskog, Noruega, 1478
- Akershus University Hospital
-
-
-
-
-
Bydgoszcz, Polônia, 85-794
- CLINSANTE Clinical Research Centre Ewa Galczak-Nowak, Malgorzata Trzaska
-
Częstochowa, Polônia, 42-202
- Synexus Polska Sp. Z o.o. Branch in Czestochowa
-
Elblag, Polônia, 82-300
- St. John Paul 2nd Municipal Hospital in Elblag, Department of Internal Diseases
-
Gdansk, Polônia, 80-382
- Synexus Polska Sp. z o.o. Branch in Gdansk
-
Katowice, Polônia, 40-040
- Synexus Polska Sp. z o.o. Branch in Katowice
-
Krakow, Polônia, 31-506
- Topolowa Medicenter
-
Krakow, Polônia, 31-156
- Landa Specialist Doctor's Offices
-
Krakow, Polônia, 30-363
- PLEJADY Medical Centre
-
Kłodzko, Polônia, 57-300
- GLOBE Clinical Research
-
Lodz, Polônia, 90-752
- IP Clinic
-
Nowy Targ, Polônia, 34-400
- Non-Public Healthcare Facility Allmedica Clinical Trials
-
Poznan, Polônia, 60-702
- Synexus Polska Sp. z o.o. Branch in Poznan
-
Poznan, Polônia, 54-144
- EMC Medical Institute Joint Stock Company, Certus Private Healthcare Facility Hospital No. 1
-
Poznan, Polônia, 54-144
- EMC Medical Institute Joint Stock Company, Penta Hospitals Clinics, Wroclaw Wejherowska
-
Poznan, Polônia, 60-529
- SOLUMED Medical Center
-
Sopot, Polônia, 81-756
- Endoskopia Sp. z o.o. (LLC)
-
Staszów, Polônia, 28-200
- New health-CK, Kieltucki and partners g.p.
-
Szczecin, Polônia, 71-685
- SONOMED
-
Szczecin, Polônia, 71-434
- TWOJA PRZYCHODNIA Medical Centre of Szczecin
-
Torun, Polônia, 87-100
- Torun Gastrology Centre Gastromed
-
Wadowice, Polônia, 34-100
- NZOZ Formed
-
Warsaw, Polônia, 02-672
- Synexus Polska Sp. z o.o. Branch in Warsaw
-
Warsaw, Polônia, 04-501
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polônia, 00-189
- MDM Healthcare Centre
-
Warsaw, Polônia, 02-786
- WSD Medi
-
Wroclaw, Polônia, 52-416
- Medical Centre Oporow
-
Wroclaw, Polônia, 53-673
- FutureMeds Wroclaw
-
Wroclaw, Polônia, 53-149
- VISTAMED
-
Wroclaw, Polônia, 53-611
- Melita Medical Medical Center
-
Zamość, Polônia, 22-400
- ETG Zamosc
-
Łęczna, Polônia, 21-010
- Independent Public Healthcare Center in Leczna
-
-
-
-
-
London, Reino Unido, SE1 9RT
- Guy's Hospital
-
-
-
-
-
Brno, Tcheca, 615 00
- Military Hospital Brno
-
Klatovy, Tcheca, 339 01
- GASTRO JeKa s.r.o.
-
Slaný, Tcheca, 274 01
- Hospital Slany
-
-
-
-
-
Chernivtsi, Ucrânia, 58002
- Regional Communal Noncommercial Enterprise: Chernivtsi Regional Clinical Hospital, Department of Gastroenterology
-
Ivano-Frankivsk, Ucrânia, 76008
- Communal Non-Profit Enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council
-
Lviv, Ucrânia, 79000
- University Hospital branch of State Non-Profit Enterprise Danylo Halytsky Lviv National Medical University
-
Lviv, Ucrânia, 79010
- Municipal Non-Profit Enterprise Lviv Territorial Medical Union Multidisciplinary Clinical Hospital of Emergency and Intensive Ca
-
Lviv, Ucrânia, 79010
- University Hospital of the State Non-Profit Company Danylo Halytsky Lviv National Medical University, Clinic of Surgery, Proctol
-
Uzhhorod, Ucrânia, 88018
- Public Non-Profit Enterprise Andrii Novak Zakarpattia Regional Clinical Hospital under Zakarpattia Regional Council
-
Vinnytsia, Ucrânia, 21018
- Municipal Non-Profit Enterprise Vinnytsia Regional Clinical Hospital named after M.I. Pirogov Vinnytsia Regional Council, Depart
-
Vinnytsia, Ucrânia, 21018
- National Pirogov Memorial Medical University, University Clinic of Vinnytsia National Pirogov Memorial Medical University (Treat
-
-
-
-
-
Vienna, Áustria, 1090
- Medical University Vienna
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Maintenance Period- Participants who achieved clinical response and/or clinical remission at week 14 of TV48574-IMM-20036 (the 14-week DRF study) or in the re-induction period of this study.
- Re-induction- Participants who did not achieve clinical response and/or clinical remission at week 14 of the TV48574-IMM-20036 DRF study
NOTE- Additional criteria may apply, please contact the investigator for more information
Exclusion Criteria:
- Participants who discontinued the TV48574-IMM-20036 study before scheduled week 14 visit (any reason including lack of efficacy, safety, or personal reasons)
- Participant has any concomitant conditions or treatments that could interfere with study conduct, influence the interpretation of study observations/results, or put the participant at increased risk during the study as judged by the investigator and/or the clinical study physician.
- Participant anticipates requiring major surgery during this study.
- Participant is currently pregnant or lactating or is planning to become pregnant or to lactate during the study or for at least 50 days after administration of the last dose of IMP in case of early termination. Any woman becoming pregnant during the study will be withdrawn from the study.
NOTE- Additional criteria apply, please contact the investigator for more information
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: TEV-48574 Dose Regimen A for Ulcerative Colitis (UC)
Administered by subcutaneous infusion for participants with UC |
Subcutaneous (sc) administration using a commercial sc infusion system
Outros nomes:
|
|
Experimental: TEV-48574 Dose Regimen A for Crohn's Disease (CD)
Administered by subcutaneous infusion for participants with CD |
Subcutaneous (sc) administration using a commercial sc infusion system
Outros nomes:
|
|
Experimental: TEV-48574 Dose Regimen B for Ulcerative Colitis (UC)
Administered by subcutaneous infusion for participants with UC |
Subcutaneous (sc) administration using a commercial sc infusion system
Outros nomes:
|
|
Experimental: TEV-48574 Dose Regimen B for Crohn's Disease (CD)
Administered by subcutaneous infusion for participants with CD |
Subcutaneous (sc) administration using a commercial sc infusion system
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with moderate to severe ulcerative colitis (UC) who show clinical remission as defined by the Mayo score
Prazo: Week 44
|
Clinical remission based on modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of ≤2 points, which is defined by:
|
Week 44
|
|
Number of participants with moderate to severe Crohn's disease (CD) who show an endoscopic response as defined by the Endoscopic Score for Crohn's Disease
Prazo: Week 44
|
Endoscopic response, defined as a decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) of at least 50% from DRF study baseline at week 44 in participants with CD |
Week 44
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Número de participantes ADA positivos com presença de ADA neutralizante
Prazo: Semanas 0, 4, 8, 16, 28, 44 e 48
|
Semanas 0, 4, 8, 16, 28, 44 e 48
|
|
|
Número de participantes que pararam de tomar o medicamento experimental (ME) devido a eventos adversos no período duplo-cego
Prazo: Até a semana 48
|
Até a semana 48
|
|
|
Número de participantes que pararam de tomar o medicamento experimental (ME) devido a eventos adversos no período aberto (OL)
Prazo: Até 5 anos após o início do período OL
|
Até 5 anos após o início do período OL
|
|
|
Número de participantes com anticorpos antidrogas (ADA) emergentes do tratamento
Prazo: Semanas 0, 4, 8, 16, 28, 44 e 48
|
Semanas 0, 4, 8, 16, 28, 44 e 48
|
|
|
Number of participants with moderate to severe UC with a clinical response as defined by Mayo score
Prazo: Week 44
|
Clinical response at week 44, defined as a decrease from baseline in the modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of at least 2 points AND at least a 30% reduction from DRF baseline with either a decrease in rectal bleeding subscore of at least 1 or an absolute rectal bleeding subscore of less than or equal to 1 |
Week 44
|
|
Number of participants with moderate to severe UC with Endoscopic improvement as defined by Mayo score
Prazo: Week 44
|
Endoscopic improvement defined as a Mayo endoscopic subscore of 0 or 1 |
Week 44
|
|
Number of participants with moderate to severe UC in Endoscopic remission as defined by Mayo score
Prazo: Week 44
|
Endoscopic remission defined as a Mayo endoscopic subscore of 0 |
Week 44
|
|
Number of participants with moderate to severe UC with Corticosteroid-free clinical remission based on the modified Mayo score
Prazo: Week 44
|
Defined by clinical remission and corticosteroid-free for ≥12 weeks preceding week 44 |
Week 44
|
|
Number of participants with moderate to severe CD with a clinical response based on Crohn's Disease Activity Index
Prazo: Week 44
|
Clinical response defined as a ≥100-point decrease from DRF baseline Crohn's Disease Activity Index (CDAI) score |
Week 44
|
|
Number of participants with moderate to severe CD in clinical remission as defined by CDAI score
Prazo: Week 44
|
Clinical remission defined as a CDAI score less than 150 |
Week 44
|
|
Number of participants with moderate to severe CD with Corticosteroid-free endoscopic response based on SES-CD
Prazo: Week 44
|
Defined by endoscopic response and corticosteroid-free for ≥12 weeks preceding week 44 |
Week 44
|
|
Number of participants with moderate to severe CD with Corticosteroid-free clinical remission based on CDAI
Prazo: Week 44
|
Defined by a CDAI score of <150 points and corticosteroid-free for ≥12 weeks preceding week 44 |
Week 44
|
|
Number of participants who experience adverse events in the double-blind period
Prazo: Up to Week 48
|
Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions. |
Up to Week 48
|
|
Number of participants who experience adverse events in the open-label (OL) period
Prazo: Up to 5 years after start of OL period
|
Adverse events can include any of the following clinically significant changes in clinical laboratory test results (serum chemistry, hematology, and urinalysis), vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate), 12-lead electrocardiogram (ECG), and injection site reactions. |
Up to 5 years after start of OL period
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Diretor de estudo: Teva Medical Expert, MD, Teva Branded Pharmaceutical Products R&D LLC
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- TV48574-IMM-20038
- 2022-002593-89 (Identificador de registro: EudraCT (EU))
- 2024-515027-11-00 (Identificador de registro: CTIS (EU))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be assessed for scientific merit, product approval status, and conflicts of interest. If the request is approved, patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .